As we continue our firm's litigation for Actos bladder cancer clients,
there is a medical study now linking other diabetes drugs to cancer: Byetta
to pancreatic and thyroid cancers, and Januvia/Janumet to pancreatic cancers.
A medical team at the University of California, Los Angeles, published
a study in the Gastroenterology Medical Journal finding a statistically
significant increased pancreatic cancer risk (Byetta 2.9-fold, Januvia/Janumet
2.7-fold), as well as a 4-fold increase for thyroid cancer in Byetta users.
Thyroid cancer was originally found in pre-market animal studies. These
drugs are associated with substantial increases in pancreatitis, a dangerous
inflammation in the pancreas. Inflammation is associated with increased
cancer risk, and the medical researchers have surmised that these drugs
stimulate pre-cancerous cells which would otherwise be harmless. Both
Paul and David Rheingold are are using their Actos bladder litigation
experience to evaluate potential claims for Byetta and Januvia/Janumet users.
